NOVARTIS TO PAY $72 MILLION TO SETTLE FALSE CLAIMS ACT FOR OFF LABEL MARKETING
Novartis Pharmaceuticals has agreed to pay over $72 million to settle a False Claims Act case charging a predecessor company, Chiron, with off-label marketing of the cystic fibrosis drug TOBI. The federal share of the settlement is $43.5 million, with $29 million go to the states.